ArticleScientific reports2015
Multiple B-cell epitope vaccine induces a Staphylococcus enterotoxin B-specific IgG1 protective response against MRSA infection.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- PLGA-PEG Nano-Adjuvant-Delivered ClfA Vaccine Elicits IL-17A-Mediated Neutrophil Activation to Confer Complete Protection Against Methicillin-ResistantInternational journal of nanomedicine · 2026Article
- Taming Superbugs: Current Progress and Challenges in Combating ESKAPE Pathogens.Pathogens (Basel, Switzerland) · 2025Review
- Protective effects of Staphylococcal Enterotoxin B (SEB) toxoid on lung and liver tissue integrity in rats during systemic infection.Iranian journal of microbiology · 2025Article
- Epitope-Based Vaccines: The Next Generation of Promising Vaccines Against Bacterial Infection.Vaccines · 2025Review
- Integrated immunodominant epitope discovery for dual-purpose rapid and economical diagnostic and immunoprotective applications against MRSA.Frontiers in immunology · 2025Article
- miR-378a-5p targeting BRAF regulates CD4Frontiers in immunology · 2025Article
- A highly neutralizing human monoclonal antibody targeting a novel linear epitope on staphylococcal enterotoxin B.Human vaccines & immunotherapeutics · 2024Article
- Changes in intestinal flora of mice induced by rEg.P29 epitope peptide vaccines.Immunity, inflammation and disease · 2023Article
- In silico designed Staphylococcus aureus B-cell multi-epitope vaccine did not elicit antibodies against target antigens suggesting multi-domain approach.Journal of immunological methods · 2022Article
- Antibiotic Combined with Epitope-Specific Monoclonal Antibody Cocktail Protects Mice Against Bacteremia and Acute Pneumonia from Methicillin-ResistantJournal of inflammation research · 2021Article
- EpiMix Based Novel Vaccine Candidate forInternational journal of peptide research and therapeutics · 2021Article
- Novel Chimeric Multiepitope Vaccine for Streptococcosis Disease in Nile Tilapia (Oreochromis niloticus Linn.).Scientific reports · 2020Article
- Article
- Protective effects of a nanoemulsion adjuvant vaccine (2C-Staph/NE) administered intranasally against invasiveRSC advances · 2018Article
- Article
- Vaccination with a Paramyosin-Based Multi-Epitope Vaccine Elicits Significant Protective Immunity againstFrontiers in microbiology · 2017Article
- Epitomics: IgG-epitome decoding of E6, E7 and L1 proteins from oncogenic human papillomavirus type 58.Scientific reports · 2016Article
- New Is Old, and Old Is New: Recent Advances in Antibiotic-Based, Antibiotic-Free and Ethnomedical Treatments against Methicillin-Resistant Staphylococcus aureus Wound Infections.International journal of molecular sciences · 2016Review
- Article
- Toxoplasma gondii Suppresses Th2-Induced byIranian journal of parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
No vaccine against methicillin-resistant Staphylococcus aureus (MRSA) has been currently approved for use in humans. Staphylococcus enterotoxin B (SEB) is one of the most potent MRSA exotoxins. In the present study, we evaluated the efficacy and immunologic mechanisms of an SEB multiple B-cell epitope vaccine against MRSA infection. Synthetic overlapping peptide ELISA identified three novel B-cell immunodominant SEB epitopes (in addition to those previously known): SEB31-48, SEB133-150, and SEB193-210. Six B-cell immunodominant epitopes (amino acid residues 31-48, 97-114, 133-150, 193-210, 205-222, and 247-261) were sufficient to induce robust IgG1/IgG2b-specific protective responses against MRSA infection. Therefore, we constructed a recombinant MRSA SEB-specific multiple B-cell epitope vaccine Polypeptides by combining the six SEB immunodominant epitopes and demonstrated its ability to induce a robust SEB-specific IgG1 response to MRSA, as well as a Th2-directing isotype response. Moreover, Polypeptides-induced antisera stimulated synergetic opsonophagocytosis killing of MRSA. Most importantly, Polypeptides was more effective at clearing the bacteria in MRSA-infected mice than the whole SEB antigen, and was able to successfully protect mice from infection by various clinical MRSA isolates. Altogether, these results support further evaluation of the SEB multiple B-cell epitope-vaccine to address MRSA infection in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.